This review highlights the complex mechanotransduction pathways in cardiac myocytes that contribute to pathological hypertrophy and fibrosis.
Answers are grounded in this paper and cite their sources.
Stretch-activated pathways may guide anti-remodeling drug development; leaves open whether modulation improves clinical outcomes in heart failure.
Cardiac myocytes react to diverse mechanical demands with a multitude of transient and long-term responses to normalize the cellular mechanical environment. Several stretch-activated signaling pathways have been identified, most prominently guanine nucleotide binding proteins (G-proteins), mitogen-activated protein kinases (MAPK), Janus-associated kinase/signal transducers and activators of transcription (JAK/STAT), protein kinase C (PKC), calcineurin, intracellular calcium regulation, and several autocrine and paracrine factors. Multiple levels of crosstalk exist between pathways. The cellular response to changes in the mechanical environment can lead to cardiac myocyte hypertrophy, cellular growth that can be accompanied by pathological myocyte dysfunction, and tissue fibrosis. Several candidates for the primary mechanosensor in cardiac myocytes have been identified, ranging from stretch-activated ion channels in the membrane to yet-unknown mechanosensitive mechanisms in the nucleus. New and refined experimental techniques will exploit advances in molecular biology and biological imaging to study mechanotransduction in isolated cells and genetically engineered mice to explore the function of individual proteins.
No takes yet. Share an insight, caveat, or question.
Lammerding et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: